Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective comparison of viscoelastic coagulation monitor (VCM) and rotational thromboelastometry (ROTEM) in the assessment of cirrhosis coagulopathy.

Thrombosis research·2026
Same author

Letter to the Editor: Liver transplantation in AH-ACLF-Which condition drives post-transplant outcomes?

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Physical frailty is the most important predictor of early mortality in hospitalized patients with decompensated cirrhosis.

Hepatology communications·2026
Same author

Extracellular Vesicles Reflect Thrombo-Inflammatory, Endothelial and Tissue-Remodelling Changes in Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Special Populations: Hepatocellular Carcinoma Risk and Liver Transplantation.

Clinics in liver disease·2026
Same author

Twenty-Year Trends in Liver Transplantation Among Hepatitis D Virus-Infected Patients in the United States and Europe.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Hepatitis C.

Patrizia Burra1

  • 1Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy. burra@unipd.it

Seminars in Liver Disease
|February 25, 2009
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) recurrence after liver transplantation is common and can lead to cirrhosis. Pretransplant antiviral treatment is a potential strategy, but optimal drug regimens and timing require further research.

More Related Videos

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Experiment Videos

Last Updated: Jun 25, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Area of Science:

  • Hepatology
  • Transplantation Immunology
  • Virology

Background:

  • Hepatitis C virus (HCV) is a primary cause of end-stage liver disease and the leading indication for liver transplantation in the US and Europe.
  • HCV recurrence post-transplantation affects most patients, with 10-25% developing cirrhosis within 5-10 years, often leading to graft failure.

Purpose of the Study:

  • To review strategies for limiting virological HCV recurrence post-liver transplantation.
  • To discuss the challenges and uncertainties in managing recurrent HCV, including optimal antiviral treatment and its timing.

Main Methods:

  • Review of existing literature on HCV recurrence after liver transplantation.
  • Analysis of risk factors, treatment strategies, and outcomes associated with recurrent HCV.
  • Discussion of pharmacokinetic considerations and drug dosage in cirrhotic patients.

Main Results:

  • HCV recurrence is nearly universal after liver transplantation, posing a significant threat to graft survival.
  • Current treatment with interferon and ribavirin has limitations, and optimal management of side effects and treatment initiation remains controversial.
  • Factors like older donor age are linked to aggressive recurrence, while the role of immunosuppression is unclear.

Conclusions:

  • Further research is needed on pretransplant antiviral therapy, including pharmacokinetics, optimal dosing, and duration.
  • Establishing clear guidelines for initiating antiviral treatment based on fibrosis progression and excluding contraindications is crucial.
  • Managing increasing numbers of retransplantation requests due to recurrent HCV requires further investigation and preparedness.